CLEC4M and colonic neoplasm: The results showed that serum DC-SIGNR levels were significantly different between colon cancer patients in stage III/IV (88.16 ± 51.78 ng/ml) and healthy individuals (47.72 ± 24.94 ng/ml) (P < 0.0001) (Fig. 6a).